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ABSTRACT
The actions of glucagon have been extensively studied for many years. In
heart, it is well established that glucagon is capable of causing inotropy. This action is
mediated by glucagon binding to a G-protein coupled receptor (GPCR) which
activates adenylate cyclase, increasing the intracellular concentrations of cAMP. The
studies that were able to show this effect used concentrations of glucagon that were
considered to be much higher than what is normally found in blood. A recent report,
by Harney and Rodgers (2008), described the actions and signaling mechanisms of
physiological concentrations of glucagon (<10-10 M) on perfused rat hearts. These
investigators were also able to show that a peak physiological concentration of
glucagon (10-10 M) increased glucose uptake in the same preparation. It was also
found that this action was mediated by the activation of the PI3K/AKT signaling
pathway. The missing piece of this mechanism to fully show glucagon’s action is the
receptor responsible for glucagon binding and initiation of the reported downstream
signaling effects. We hypothesize that one of two situations would occur: 1) the
glucagon receptor that mediates glucose uptake is a GPCR or 2) there is a novel
glucagon receptor responsible for the effects observed at low concentrations. Hearts
were removed from male Sprague Dawley rats (n=1-6/grp) and isolated heart
perfusion methods, either Langendorff or working mode, were used to deliver a
physiological solution to the heart. Specific concentrations of hormone, one which
represents peak physiological glucagon levels and another that represents a
concentration of glucagon too high to be normally found in blood, were added to the
physiological solution. An anti-glucagon receptor antibody was obtained which was

used to block the known glucagon receptor. Hearts were treated with no hormone or
with the following treatments: 1) 10-10 M glucagon; 2) 4x10-10 M insulin; 3) 10-8 M
glucagon; 4) 10-8 M glucagon plus antibody and 5) 10-10 M glucagon plus antibody.
Immediately after perfusion, hearts were processed and probed for AKT activation. It
was found that glucagon concentrations at 10-10 M did not induce an inotropic
response during Langendorff perfusion, while glucagon concentrations at 10-8 M was
able to. For working mode, an inotropic response was not observed when hearts were
perfused with 10-10 M glucagon and 10-8 M glucagon. There was no observable
activation in AKT after physiological glucagon treated hearts in either Langendorff or
working mode perfusion methods. In conclusion, the receptor that mediates
glucagon’s actions at physiological concentrations was not able to be characterized
from these experiments. Experimental strategy should be revised to optimize ex vivo
heart perfusion method and include additional in vitro experiments to conclude the
identity of the glucagon receptor.
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CHAPTER 1

INTRODUCTION
Glucagon is a 29-amino acid peptide that is manufactured in alpha cells of the
pancreas (Jiang and Zhang, 2003). This peptide is a vital player in regulating glycemia
by acting in opposition to the effects of insulin. When blood glucose and insulin are
low, the tonic inhibitory effect of insulin is removed and glucagon can be released
from the pancreas (Taborsky, 2010). Glucagon is transported in the blood to its
primary effector organ, the liver. As the ratio of glucagon to insulin increases,
glucagon’s action will be more prominent than insulin’s action (Unger, 1971). The
major effect of glucagon is to promote glucose output by increasing glycogenolysis
and gluconeogenesis. In addition, glucagon can also act on the heart and adipose tissue
by increasing contractility and lipolysis, respectively (Rodgers, 2012).
A G-protein coupled receptor (GPCR) is the main molecular target for
glucagon (Jiang and Zhang, 2003; Rodgers, 2012). GPCR’s are a type of receptor that
contains a seven-transmembrane domain plus a heterotrimeric G-protein complex
(Salazar et al., 2007). When glucagon binds to a GPCR, a signaling cascade is
initiated. First, Gαs subunits are activated and dissociate from the G-protein complex,
which causes an increase in cyclic adenosine mono-phosphate (cAMP) by increasing
the activity of a membrane-bound enzyme called adenylate cyclase (AC). cAMP then
activates protein kinase A (PKA) by binding to the regulatory subunit causing it to
dissociate from the catalytic subunit. PKA can phosphorylate certain proteins which
causes an action at the specific organ (Rababa’h et al., 2014; Towle, 2001).
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The action of glucagon has been studied for many decades. The known actions
of glucagon on liver, adipose tissue, and heart occur when glucagon binds to a GPCR
to activate the AC/cAMP dependent pathway. The problem with these described
actions is that they only occur at supra-physiological (glucagon concentration
>0.1nM) levels, which do not reflect the physiologic concentrations (glucagon
concentration <0.1nM) found in vivo (Rodgers, 2012). This was illustrated by
constructing average dose-response curves from numerous studies. For adipose and
heart, the EC50 value of glucagon to produce the organ’s specific action, and the
generation of cAMP, overlap each other and are well outside the concentration
normally found in blood (Henry et al., 1975; Jean-Baptiste et al., 1982). This supports
the claim that glucagon does not produce these actions in vivo. For liver, the EC50
value of glucagon to increase cAMP is well outside glucagon’s physiological
concentration. However, it can be shown that glucagon can cause the liver to generate
similar or identical responses at much lower concentrations without activating
adenylate cyclase (Clark and Jarrett, 1978; Ikezawa et al., 1998a). Since the curves for
glucose output and concentration of tissue cAMP do not overlap, one can make the
assertion that glucagon’s action on the liver can occur through an alternative signaling
mechanism in vivo. Collectively, these results raise the question about the
“physiological relevance” of glucagon to produce these actions via the AC/cAMP
dependent pathway. In order for a hormone’s action to be considered “physiologically
relevant”, the action of the organ must occur at concentrations normally found in
blood (Rodgers, 2012). It is evident from these graphs that glucagon can only generate
cAMP-dependent cellular effects when concentrations are well above physiological
2

levels. Thus, additional research should be conducted to elucidate the physiological
action of glucagon in liver, adipose tissue, and heart.
Studies have shown in liver that physiological and supra-physiological
concentrations of glucagon activate two different signaling pathways but cause the
same action (Livingston et al., 1985; Wakelam et al., 1986). The first piece of
evidence comes from dose-response curves. Glucagon at physiological concentrations
was able to increase glucose output without any increase in cAMP in perfused rat
livers (Pilkis et al., 1974). Binding studies were also performed and it was found that
supra-physiological glucagon concentrations were needed to activate the lower affinity
glucagon receptor linked to AC. In the study performed by Bonnevie-Nielsen and
Tager (1983), they determined Kd values for two different population of glucagon
receptors. The Kd values of the low affinity glucagon receptor was 0.54 nM in
hepatocytes and 92 nM in liver vesicles. Both these K d values are above physiological
concentrations. The high affinity receptor had Kd values of 0.19 nM and 2.6 nM in
hepatocytes and liver vesicles respectively (Bonnevie-Nielsen and Tager, 1983). At
physiological concentrations, glucagon binds with higher affinity to a receptor not
linked to AC. It was found that the high affinity receptor participated in a calciumdependent signaling pathway that also increased glucose output (Ikezawa et al.,
1998b). A molecular cloning study was performed to identify the receptor that binds to
glucagon. The experimenter expressed the glucagon receptor in kidney cell lines and
measured Kd values. According the Schatchard plot they developed, they found two
Kd values for the glucagon receptors that they expressed. However, the authors were
not able to conclude that the receptors were anything other than the GPCR (Jelinek et
3

al., 1993). Thus, one prominent hypothesis is that two glucagon receptors are GPCRs,
with two different affinities to glucagon, that can either undergo the AC/cAMP or
PLC/IP3 signaling pathways.
Adipose tissue also has been shown to respond to glucagon at supraphysiological concentrations via the cAMP/AC dependent pathway. However, the
available evidence does not support the existence of a physiological receptor for
glucagon in adipose tissue. The average dose response curves produces a monophasic
curve with an EC50 that lies well outside physiological glucagon concentrations (JeanBaptiste et al., 1982). Furthermore, the average EC50 and Kd was calculated from
many studies and it was shown that these values were similar (Rodgers, 2012). The
similar values show that an additional receptor is not present in adipose tissue. Thus,
it is believed that glucagon does not have any action in vivo on adipose tissue.
It has been demonstrated multiple times, and in many experimental models,
that glucagon causes the heart to generate more force at a faster rate. Because of this,
the claim has been made that glucagon’s acts to activate inotropic and chronotropic
responses on the heart, both which are accompanied by increase in cAMP. Dr. Robert
Rodgers and his colleagues believe that these effects cannot be the in vivo action of
glucagon because concentrations above physiological levels are needed for this to
occur. Dr. Rodgers constructed a concentration-effect curve that represents the
findings of multiple sources to show the action of glucagon on the heart (Rodgers,
2012). From his curve, he shows that EC50 values for inotropy and cAMP
concentration both lie well outside of the glucagon concentration found in blood.
Thus, his laboratory was interested in seeking out glucagon’s in vivo cardiac action.
4

They found that at physiological glucagon concentrations, glycolysis increased and
palmitate oxidation decreased in isolated perfused working hearts (Harney and
Rodgers, 2008). These actions are the same as insulin’s actions and our experiments
showed that there was no statistical difference between the actions produced by either
glucagon or insulin (Harney and Rodgers, 2008; Rodgers et al., 2001a). Furthermore, a
physiological glucagon concentration activated a PI3K/AKT pathway but had no
effect on the cAMP/AC pathway. This is another component that is shared between
glucagon and insulin (Harney and Rodgers, 2008; Saltiel and Kahn, 2001). they were
able to show that glucagon mimics the action of insulin, rather than opposing it, in
heart at a physiological concentration.
The glucagon receptor that mediates the insulin-like response has yet to be
identified. The purpose of this investigation was to begin to explore the identity of this
receptor by performing heart perfusions followed by western blot analysis. The
isolated heart perfusion method was used because the physiological parameters of the
heart could be measured independent of any neuro-hormonal influence, the heart is in
an environment where all substrates and substrate levels are known, and without an
confounding effects from other metabolically active organs (Skrzypiec-Spring et al.,
2007). Hearts were treated with specific concentrations of hormone (physiological or
supra-physiological) and contractility was measured to see if the hormone could
activate the known GPCR. To block the known GPCR, an anti-glucagon GPCR
antibody was obtained and put into a solution that was perfused through the heart.
Hearts were then subjected to western blot analysis after perfusion experiments to
show AKT activation. We hypothesized: 1) A GPCR linked to PI3K/AKT mediates
5

the insulin-like action of glucagon or 2) A receptor of a different class linked to
PI3K/akt mediates the insulin-like action of glucagon.

6

CHAPTER 2

METHODOLOGY
Methods:
Animal usage:
All procedures for the use of animals were approved by the University of
Rhode Island Animal Care and Use Committee. Male rats were purchased from
vendors (Taconic or Charles River). Animals were co-housed in standard cages with a
12-hour light-dark cycle. They provided water and standard chow ad libitum., and
body weights were collected routinely.

Preparation of solutions:
Hearts were perfused with Krebs-Henseleit (K-H) solution with the following
composition (mM): NaCl, 120; CaCl2•2H2O, 1.8; NaH2PO4•H2O 1.2; MgSO4•7H2O,
0.65 and KCl, 5.6, glucose, 10; and NaHCO3, 25. Working and Langendorff heart
preparations were perfused with K-H solution containing 3% and 0.1% BSA,
respectively. In both preparations, the solution was gassed with 95-5% O2-CO2
Hearts were treated with one of the following: 1) no hormone; 2) insulin
(4x10-10M) (Sigma-Aldrich); 3) and glucagon (10 -10 or 10-8M) (Sigma-Aldrich). The
lower and higher glucagon concentrations represented physiological and supraphysiological concentrations (Rodgers, 2012).

Isolated Heart Perfusion:
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The isolated heart perfusion technique was used to measure the hearts
contractility when administering different treatments. The two types of perfusion
techniques used were the Langendorff (Skrzypiec-Spring et al., 2007) and the working
mode preparation (Harney and Rodgers, 2008; Rodgers et al., 2001b), both which
have been described previously. Both preparation allows for the delivery of K-H
solution to the coronary arteries of the heart so it can contract without being inside the
animal. The pressure produced during perfusion was measured using a Millar catheter
(SPR-524) inside a K-H solution filled column which was connected to the left
ventricle. Pressure data was collected using Data Translation software (Colorado
Springs, CO) and the data was analyzed using ADinstruments Lab Chart software. At
the end of the perfusion, hearts were snapped frozen in liquid nitrogen and store in 80oC freezer.

Western Blot and AKT probing:
The procedure used to isolate proteins from the heart tissue was established
by Harney and Rodgers (2008). Briefly, left ventricles of the heart were isolated then
added to a lysis buffer containing the following solutes (mM) NaCl – 150; Tris-HCl –
50; NaVO4 – 1; EDTA – 5; PMSF – 1; and protease tablet. Tissues were homogenized
and centrifuged at the following speeds (times g): 1,000; 100,000; and 15,000. The
final solution contained only soluble proteins. Proteins in solution were quantified
using BCA assay kit.
Protein in solution were separated via SDS-PAGE. Equal amount of protein
was added to each lane of a 10% gel and were electrophoresed at 100V. At the
8

completion of the electrophoresis, electroblotting was performed to transfer proteins
from the polyacrylamide gel to a PVDF membrane. Electroblotting proceeded at 30V
for 30 minutes.
Anti-AKT and anti-phospho-AKT (S473) were purchased from Cell
Signaling Technologies and were used according to manufacturer’s protocol. Proteins
were visualized using Biorad ChemiDoc imaging. ImageJ software was used to
quantify the signal that was developed by the imaging software.
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CHAPTER 3

FINDINGS

It is well established that high concentrations of glucagon are capable of
inducing an inotropic response on the heart (Gonzalez-Muñoz et al., 2008; MacLeod
et al., 1981; Rodgers et al., 1981). This response is mediated by the known glucagon
GPCR linked to AC/cAMP. Physiological glucagon concentrations and insulin should
not be able to induce this response (Fu et al., 2014; Harney and Rodgers, 2008).
Therefore, we tested this theory by administering either 0.4 nM of insulin, 0.1 nM
(physiological concentration) or 10nM (supra-physiological) of glucagon to isolated
perfused hearts and measure the pressure produced by the left ventricle.
Figure 1 is a representative pressure tracing of one heart perfused via the
Langendorff preparation. From this figure, the left ventricular developed pressure
(LVDP) can be determined by taking the difference between the peak systolic and
diastolic pressures. The developed pressures were calculated for each heart and the
average pressures were determined for each hormone group. The average LVDP
values are represented in figure 2. Hearts that were perfused with no hormone had an
average pulse pressure of 65.6 +/- 7.06 mmHg (mean +/- SEM). When 0.4nM insulin
or 0.1nM of glucagon the pressure produced were 68.02 +/- 13.11 mmHg and 80.67
+/- 19.78 mmHg, respectively. This is in line with what we were expecting because
peak physiological concentration of either insulin or glucagon is not capable of
inducing inotropy (Fu et al., 2014; Harney and Rodgers, 2008). Hearts produced the
10

largest inotropic response after administration of glucagon at supra-physiological
concentrations, as expected. The pressure that was developed for supra-physiological
glucagon administration was 133.11 +/- 6.67 mmHg.
Hearts that were perfused via working mode produced higher pressures, with
all treatments, compare to hearts perfused in the Langendorff mode. Figure 3 is a
representative pressure tracing of a heart perfused in the working mode. The same
calculations were performed, as for figure 1, and average pressures were determined
for each group and are represented in figure 4. Hearts produced pressures of 110.80
+/- 10.7 mmHg, 100.85 mmHg, 90.95 +/- 24.6 mmHg and 92.96 +/- 4.18 mmHg when
administered with no hormone, 0.4nM insulin, 0.1nM glucagon, and 10nM glucagon
respectively. Unlike what was observed in hearts administered with 10nM glucagon
via Langendorff perfusion, the average pressure of 10nM glucagon was less than that
of control in the working mode. Figures 5 and 6 are representative tracings of a heart
perfused with a supra-physiological glucagon concentration. It can be seen that an
increase in contractility did occur. However, the response eventually decreased as the
heart progressed through the perfusion which explains why the average pressure was
less than control (figure 7).
It has been determined in this laboratory that, not only does a physiological
concentration of glucagon mimic the same physiological action of insulin in the heart,
but it also shares the same signaling pathway (Harney and Rodgers, 2008). It is well
established that insulin binds to the insulin receptor which activates PI3K followed by
AKT to increase glycolysis (Lee and Pilch, 1994). Evidence from this laboratory
shows that glucagon at physiological concentrations also activates the PI3K/AKT
11

signaling pathway. Thus, we used this signaling pathway to assess the claim that
changes in cardiac glycolysis could occur independently of changes in cardiac
contractility with physiological concentrations of glucagon. The PI3K/AKT signaling
pathway was quantified by measuring total amounts of AKT and the amount of
phosphorylated AKT. A phosphorylated AKT:total AKT ratio was calculated to assess
the activation of this signaling pathway when a hormone is given to the heart. For
hearts perfused in Langendorff mode, an average P-AKT/T-AKT of 0.468 +/- 0.076
(mean +/- SEM) was observed for untreated hearts. The highest P-AKT/T-AKT ratio
that was observed was when insulin was administered to the hearts (0.561 +/- 0.128).
Supra-physiological glucagon concentrations produced the second highest ratio of
0.603 +/- 0.236. Administration of physiological glucagon produced the smallest a PAKT/T-AKT ratio of 0.221 +/- 0.032.
AKT quantification was also assed in hearts perfused in the working mode. A
value of 0.468 +/- 0.076 was observed for untreated hearts. Administration of insulin
to hearts gave the highest P-AKT/T-AKT ratio compared to the other groups (1.168).
Supra-physiological glucagon produced the second highest P-AKT/T-AKT ratio of
0.719 +/- 0.068. Finally, administering physiological glucagon produced an P-AKT/TAKT ratio of 0.472. +/- 0.099.
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CHAPTER 4

CONCLUSION

The quintessential action of glucagon is to increase contractility of the heart.
However, studies proved that this only happens at supra-physiological concentrations.
In the laboratory of Dr. Robert Rodgers, they were able to find a different action of
glucagon at physiological concentrations. Glucagon increased glucose uptake, glucose
oxidation, and decreased palmitate oxidation to a degree similar to insulin (Harney and
Rodgers, 2008; Rodgers et al., 2001a). Furthermore, physiological concentrations of
glucagon activated the PI3K/AKT pathway without any activation of AC/cAMP
(Harney and Rodgers, 2008). Therefore, we believe that increasing cardiac
contractility is not the main in vivo action of glucagon.
The first objective of this study was to determine whether a supraphysiological concentration of glucagon increases inotropy compared to physiological
concentrations in Langendorff perfused hearts. A supra-physiological concentration of
glucagon was able to produce an average LV pulse pressure that was greater compared
to controls in Langendorff perfused hearts. Hearts perfused with a physiological
concentration of glucagon or insulin produced LV pressures that were modestly
elevated compared to control hearts. This result was consistent with previous reports
(Harney and Rodgers, 2008; Tuncok et al., 1997). Hearts perfused with any of the
hormone treated groups, in working mode, did not produce an average LV pulse
pressure that was larger compared to controls. An inotropic response was expected to
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occur in hearts treated with supra-physiological glucagon concentrations because it
has been previously reported that high glucagon concentrations increase developed
tension or pressure in rat hearts or cardiac muscle preparations (MacLeod et al., 1981;
Rodgers et al., 1981). Although the average response was not different, it appears that
a transient inotropic response was produced. This observation can be explained by
glucagon’s tachyphylaxis response. Tachyphylaxis response, in heart, occurs when
there is a rapid increase in left ventricular pressure which is then decreases back to
baseline shortly after (MacLeod et al., 1981). This response occurs in G-protein
signaling due to either receptor desensitization or by activity of phosphodiesterases
that degrades cAMP. Fita-Juan and colleagues (2004), studied the tachyphylaxis
response in isolated right ventricle strips in rats. When glucagon was added to these
hearts, a transient (< 2min) inotropic response was induced (Juan-Fita et al., 2004). In
this study, it was observed that the inotropic response was at its highest point one
minute after glucagon administration, then rapidly decreased.
The second objective was to determine whether a physiological concentration
of glucagon was able to activate the PI3K/AKT signaling pathway. We evaluated
activation of PI3K/AKT pathway by quantifying phosphorylated AKT and total AKT
via western blots. For Langendorff and working mode perfused hearts, there appears
to be no increase in AKT activation between physiological glucagon treated hearts
compared to untreated hearts. This was contrary to Harney and Rodgers’s report which
showed PI3K/AKT activation when hearts were perfused with low concentrations of
glucagon. A physiological concentration of insulin produced more activation in AKT
compared to untreated hearts in either Langendorff or working mode perfusion
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methods. Due to the small number of subjects in the insulin treated group, the values
obtained cannot definitively show that insulin was capable of activating AKT at a
higher magnitude compared to untreated hearts.
Differences in methodology could explain the unexpected results that were
observed in this experiment. One factor that may explain the discordant results is the
difference in the age range of rats enrolled in each study. In the current experiment,
the age was not recorded but, the age can be approximated using body weight (2017).
Harney and Rodgers (2010), used rats that weighed between 200-400 grams which
approximates to two to three months. In this experiment, it was noted that many of the
animals that were used weighed over 400 grams with is approximately three months or
older.
Another point that arises, due to the unexpected results, is whether or not the
glucagon used was sufficient to activate AKT. The glucagon that was used may have
lost intrinsic activity to activate the glucagon receptor, or, the dilution procedure was
not accurate and low than expected concentrations of glucagon was administered to
the perfused heart. A crucial experiment that can give evidence to the integrity of the
glucagon solution was to perfuse hearts with 5-3H-glucose and measure the change in
rate of glycolysis. If glucagon administration was able to activate glycolysis, but not
PI3K/AKT, then it can be argued that glucagon’s physiological actions are not
mediated by PI3K/AKT.
Aging can affect the biochemical and physiological parameters of this
experiment. First, the strength of the PI3K/AKT signaling pathway could have
decreased due to using older rats. Griecsova and colleagues (2015), showed that three-
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month-old rats had a lower AKT activation than 1.5 months old rats (Griecsová et al.,
2015). In this study, several rats weighed over 400 grams which approximate to a 3month-old rat. This may explain why AKT activation was not as robust as expected
after insulin treatment. This could also be a factor that cause physiological glucagon
treated hearts to have a lower than expected AKT activation.
A decline in cardiac performance can also be attributed to changes in the
GPCR receptor signaling. These changes include reductions in the: 1) number of
receptors, 2) sensitivity of the receptor and 3) downstream actions after receptor
activation. In a study performed by Xiao et al (1998), they found that age related
declines in LV contractility were due to decreases in the number of β-adrenergic
receptors. It was also determined from this study that older rats have less AC activity
compared to young rats when a ligand binds to the receptors (Xiao et al., 1998).
Furthermore, heart contractility decreased due to changes in calcium handling after βadrenergic stimulation. It was found that calcium levels were decreased in older
animals compared to younger ones which will reduce the strength of contraction
(Ferrell and Howlittt 2007). It was shown that decreases in calcium levels during
diastole can decrease the contraction force at the next heartbeat. Since the glucagon
receptor is also a GPCR associated with AC, it can be expected that similar changes
can occur due to aging which may have affected the hearts ability to contract.
Fibrosis of heart tissue is another possible factor that may explain the lower
than expected pressure produced by the hearts. Age-related fibrosis increases collagen
deposits into the heart’s extracellular matrix and causes a decrease in performance. In
ideal conditions, the extra cellular matrix plays an important role in maintaining the
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organs structure that allows it to work normally (Heeneman et al., 2003). For certain
conditions (i.e. aging) there may be an overproduction of extracellular matrix proteins
which decreases the hearts ability to perform. In an experiment conducted by
Sangaralingham et al., they showed that collagen production in the left ventricle was
higher in 20-month-old Fisher rats than in two- months old rats (Sangaralingham et al.,
2016). This increase in fibrosis was accompanied by decreases in ejection fracture and
decreases in diastolic wall tension.
Evidence is also present that shows young Sprague-Dawely rats are prone to
develop spontaneous cardiac lesions. In a study conducted by Chanut et al. (2013),
they looked at the presence of lesions in different regions of the heart and they found
the highest occurrence of lesions to be within the myocardium of the left ventricle. It
was also reported that the stress from handling the rats had no effect on changing the
occurrence of the lesions (Chanut et al., 2013). This can have an effect on the pressure
generated by the heart. The presence of cardiac lesion can cause an inflammation
response that may release factors which can decrease LV function. For example, it has
been shown that TNF (a pro-inflammatory agent) infusion resulted in reduced
inotropic response which was reversed when TNF was removed (Mann, 2002).
Depending on the size and number of lesions in the heart, this may have contributed to
the lower than expected pressure development of the left ventricle.
If this experiment was to be redone, a different approach for identifying the
PI3K/AKT signaling pathway would be necessary. One method that can be utilized are
cell culture techniques followed by western blot analysis to probe the same proteins.
Isolated cardiomyocytes can be obtained from whole heart by perfusing it with
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digestive enzymes via Langendorff perfusion (Louch et al., 2011). The isolated cell
can then be plated onto a culture dish and be given culture media. In the culture media,
different concentrations of hormone can be given to the cardiomyocytes and protein
quantification can be determined via western blotting.
Western blot analysis have been performed on hepatocytes and probed for
AKT (Aw et al., 2014; Zhao et al., 2000). In these experiments, glucagon was not able
to activate the PI3K/AKT signaling pathway. This observation can be explained by the
fact that the receptors present in the liver are not linked to PI3K/AKT. However, this
author was not able to find any reports that performed cell culture experiments on
isolated ventricular cardiomyocytes treated with glucagon. Performing this method
may provide evidence on the physiological signaling cascade of glucagon.
Instead of using ex vivo hemodynamics to measure the contractility of the
heart, in vitro video edge detection of isolated ventricular cardiomyocytes could be
used to measure a single myocyte’s ability to shorten (Bazan et al., 2010). There is
evidence that the cardiomyocyte has glucagon receptors on it so the changes in
contractility can be measure when cell are perfused with glucagon containing solution
(Ali et al., 2015; Méry et al., 1990; Tang and Insel, 2004). It has the advantage over ex
vivo measurements of contractility because the experimenter is directly measuring the
ability of a single myocyte to shorten when given a certain stimulus. The contractility
of many myocytes can be measured which may provide evidence for how the cells
will function in the intact organ. A limitation of this method is that the results may not
represent what is occurring at the organ level. Whole heart perfusion methods
incorporate preload and after load, both which influence the tension that can be
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developed in the LV (Schechter et al., 2014). Furthermore, measuring contractility in
isolated cardiomyocytes does not represent how the heart may act in vivo because the
cells are not connected to each other. Gap junctions are channels which connect the
intracellular content between two cardiomyocytes. These channels allow ionic current
to pass directly from one cardiomyocyte to another which allow the whole heart to
contract in a synchronized manner (Rook et al., 1992). Interruption of this current
through each cardiomyocyte can prevent the ventricles from depolarizing and thus fail
to contract. Contractility can be measured using cell based experiments. Threedimensional cell culture techniques allow for an experimenter to grow cells that does
not limit the cells to grow on a flat surface. Cells are able to form connections with
each other that may closer replicate what happens in vivo. In a report by Shimizu et al.,
they were able to measure cell shortening in cultured cardiac tissue grafts by using a
digital video camera (Shimizu et al., 2002).

Limitations:
The surgical procedure used in this study was similar to the procedure
performed by Harney and Rodgers (2010). The experimenter tried to replicate the
same conditions that Harney used when performing the heart isolation, but the
experimenter was not there to observe Harney perform the procedure. It was thought
that differences in experimenter’s ability to isolate the heart could have contributed to
the different results. Differences such as speed of heart isolation and location of
cannula placed on the aorta could have affected the outcome of the procedure. Using
anesthesia could have facilitated in the heart isolation process by reducing the stress
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put on the animal. Minimizing the stress on the heart may reduce the damage put on
the heart while the experimenter performs the heart isolation procedure.
Another limitation of this experiment is that absolute pressure values were
recorded, rather than changes in pressure relative to baseline. Changes in LV pulse
pressure from baseline is a better marker for contractility. The reason is that there are
many factors that can influence the amount of force the heart can produce; such as
changes in pre-load and afterload, health of the heart, or quality of solutions used to
treat heart. Contractility is the heart’s ability to increase the amount of force
independent of pre-load and/or after load. Recording the change in LV pulse press will
rule out some of the effects of extrinsic factors that may change the pressure the heart
produces. With absolute pressures, we can see that different pressures are generated
but we cannot fully conclude that the pressures generate was due to the heart’s
intrinsic ability to develop more force.

Conclusion
In summary, it cannot be determined if a high concentration of glucagon was
able to induce an inotropic response. LV pressure was the highest in supraphysiological treated hearts perfused in Langendorff mode. However, LV pressure
was similar between untreated and supra-physiological glucagon administered hearts.
The data also shows that there were no changes in AKT activation among the four
groups. A limitation in this study that can explain why difference in measurements
were not detected were due to the number of rats in each group. Since some of the
treatment groups had less than four animals, statistics were not able to be performed to
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determine if there was a difference in values for LV pressure development and AKT
activation.
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Figures

Figure 1: Representative pressure measurement for a heart perfused in the Langendorff
preparation. This graph was shows the pressure produced by the left ventricle after 1
minute of perfusion. The difference between the maximum and minimum pressure
were averaged to determine pulse pressure. This heart was treated with no hormone.
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Figure 2: Average pulse pressure produced by each treatment. Pulse pressure was
determine by taking the difference of the average maximal pressure minus the average
minimal pressure. Bars represent average values and error bars represent the SEM.
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Figure 3: Representative pressure measurement for a heart perfused in the working
mode. This graph was shows the pressure produced by the left ventricle after 10
minute of perfusion. The difference between the maximum and minimum pressure
were averaged to determine pulse pressure. This heart was treated with no hormone.
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Figure 4: Average pulse pressure produced by each treatment. Pulse pressure was
determined by taking the difference of the average maximal pressure minus the
average minimal pressure. Bars represent average values and error bars represent SEM
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Figure 5
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Figure 6
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Figure 7
Figures 5, 6, and 7 are representative pressure tracings of one heart perfused via
working mode. A supra-physiological glucagon concentration was administered at
time zero. Each figure represents a different time point on the same heart. The
pressure was determined by taking the difference of maximum value and the minimum
value.
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Figure 8: Average ratio of P-akt/T-akt for hearts perfused in the Langendorff Mode.
Ratios represent the activation in PI3K/akt pathway. Error bars represent the SEM.
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Figure 9: Average ratio of P-akt/T-akt for hearts perfused in the working Mode. Ratios
represent the activation in PI3K/akt pathway. Error bars represent the standard
deviation. Values represent means and error bars represent SEM
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